Veracyte is trading 4.31% down now at $38.41 as biotech shares weaken and broader markets sell off amid higher rates and persistent inflation concerns.
- No clear September 16 company-specific negative catalyst was identified.
- A recent Morgan Stanley presentation highlighted slower single-digit 2026 growth for low-risk Decipher testing after a guideline change.
- Veracyte maintained profitability guidance and described continued demand.